Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 44, 2011, Pages 18097-18101

  Liberatore, Rachel A ^a   Bieniasz, Paul D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL SURFACE PROTEIN; TETHERIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; TARGET CELL; VIREMIA; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, CD; INTERFERON TYPE I; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; VIRUS REPLICATION;

MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MUS;

EID: 81055145390     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1113694108     Document Type: Article

References (34)

1. Ishikawa J, et al. (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534.
2. Kupzig S, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709. (Pubitemid 37168591)
3. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. (Pubitemid 351158893)
4. Van Damme N, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. (Pubitemid 351494713)
5. Jouvenet N, et al. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83:1837-1844.
6. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 106:2886-2891.
7. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83:2382-2385.
8. Weidner JM, et al. (2010) Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84: 12646-12657.
9. Fitzpatrick K, et al. (2010) Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog 6:e1000701.
10. Hammonds J, Wang JJ, Yi H, Spearman P (2010) Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog 6:e1000749.
11. Perez-Caballero D, et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511.
12. Jolly C, Booth NJ, Neil SJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84:12185-12199.
13. Carr JM, Hocking H, Li P, Burrell CJ (1999) Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 265:319-329. (Pubitemid 30022226)
14. Dimitrov DS, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67:2182-2190. (Pubitemid 23088394)
15. Mothes W, Sherer NM, Jin J, Zhong P (2010) Virus cell-to-cell transmission. J Virol 84: 8360-8368.
16. Sherer NM, et al. (2007) Retroviruses can establish filopodial bridges for efficient cellto- cell transmission. Nat Cell Biol 9:310-315. (Pubitemid 46344610)
17. Miyagi E, Andrew AJ, Kao S, Strebel K (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci USA 106:2868-2873.
18. Andrew A, Strebel K (2011) The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res 31:137-144.
19. Andrew AJ, Miyagi E, Kao S, Strebel K (2009) The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80.
20. Blasius AL, et al. (2006) Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 177:3260-3265. (Pubitemid 44277845)
21. Cao W, et al. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206:1603-1614.
22. Jolicoeur P (1991) Murine acquired immunodeficiency syndrome (MAIDS): An animal model to study the AIDS pathogenesis. FASEB J 5:2398-2405.
23. Mosier DE, Yetter RA, Morse HC, 3rd (1985) Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J Exp Med 161:766-784. (Pubitemid 15083776)
24. Hoshi M, et al. (2010) The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 185: 3305-3312.
25. Hasenkrug KJ, Dittmer U (2000) The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: Lessons from the Friend virus model. Virology 272:244-249. (Pubitemid 30480185)
26. Malleret B, et al. (2008) Primary infection with simian immunodeficiency virus: Plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112:4598-4608.
27. Stacey AR, et al. (2009) Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83: 3719-3733.
28. Erikson E, et al. (2011) In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci USA 108:13688-13693.
29. Homann S, Smith D, Little S, Richman D, Guatelli J (2011) Upregulation of BST-2/tetherin by HIV infection in vivo. J Virol 85:10659-10668.
30. Pattengale PK, et al. (1982) Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV). Am J Pathol 107:362-377. (Pubitemid 12084838)
31. Gupta RK, et al. (2009) Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 106:20889-20894.
32. Jia B, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5:e1000429.
33. Le Tortorec A, Neil SJ (2009) Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83:11966-11978.
34. Zhang F, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67.